Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients

Annals of Neurology

Volumn 42, Issue 5, 1997, Pages 747-755

  Kieburtz, ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENTACAPONE; LEVODOPA;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DYSKINESIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; ANTIPARKINSON AGENTS; CATECHOLS; DOUBLE-BLIND METHOD; DYSKINESIA, DRUG-INDUCED; ENZYME INHIBITORS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MOVEMENT; PARKINSON DISEASE; PATIENT COMPLIANCE; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 0030778373     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410420511     Document Type: Article

References (18)

1. Poewe W. L-dopa in PD: mechanisms of action on and pathophysiology of levodopa failure. In: Jankovic J, Tolosa E, eds. Parkinson's disease and movement disorders. 2nd ed. Baltimore: Williams and Wilkins, 1993
2. Keränen T, Gordin A, Karlsson M, et al. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol 1994;46:151-157
3. Ruottinen NM, Rinne UK. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 1996;60:36-40
4. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-919
5. Kaakkola S, Teravainen H, Ahtila S, et al. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 1994;44:77-80
6. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442
7. Lang AE, Fahn S. Assessment of Parkinson's disease. In: Munsat TL, ed. Quantification of neurologic deficit. Boston: Butterworths, 1989
8. Huynh H, Feldt LS. Estimation of the Box correction for degrees of freedom for sample data in randomized block and splitplot designs. J Educ Stat 1976;1:69-82
9. Dorflinger EE, Rajput A, the Tolcapone Fluctuator II Study Group. Multicenter evaluation of tolcapone (Tasmar) when given together with levodopa to Parkinson disease patients who exhibit end-of-dose wearing-off. Neurology 1996;46:A474-A475 (Abstract)
10. Roberts JW, Cora-Locatelli G, Bravi D, et al. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/ carbidopa action in parkinsonian patients. Neurology 1993;43:2685-2688
11. Kurth MC, Adler CH, Saint-Hilaire M, et al. Tolcapone improves motor fluctuation and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Neurology 1997;48:81-87
12. Waters CH, Kurth MC, the Tolcapone Fluctuator II Study Group. Evaluation of the efficacy and safety of tolcapone (Tasmar) in Parkinson's disease patients with a stable response to levodopa. Neurology 1996;46:A160 (Abstract)
13. Ahlskog JE, Muenter MD, McManis PH, et al. Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease. Mayo Clin Proc 1988;63:876-886
14. Hutton JT, Morris JL, Bush DF, et al. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease. Neurology 1989;39(suppl 2):67-72
15. Inzelberg R, Nisipeanu, Rabey JM, et al. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology 1996;47:785-788
16. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet® in Parkinson's disease. Mov Disord 1994;9:40-47
17. Hutton JT, Koller WC, Ahlskog JE, et al. Multicenter, placebo-controlled trial of cabergoline taken once daily in treatment of Parkinson's disease. Neurology 1996;46:1062-1065
18. Golbe LI, Lieberman AN, Muenter MD, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol 1988;11:45-55